Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Lee Feander
BIG PICTURE: Fixing the medicines shortage crisis
BY LEE FEANDER From over-the-counter flu tablets to crucial antibiotics and antidepressants, medicines are running scarce in UK pharmacies this year, causing concerns among patients, the government, and the wider pharma industry. Drug shortages have accelerated over the past year due to a clutch of problems including the after-effects of the pandemic on supply chains, the war in Ukraine, and soaring input costs weighing on manufacturers.
3 areas pharma needs to address to tackle the UK drug shortage problem
Lee Feander, senior director with Alvarez & Marsal Healthcare and Life Sciences practice, explores the three areas that pharmaceutical companies need to address to better tackle the current UK drug shortage. Key insights: Sharper forecasting means pharma companies can predict demand surges across the supply chain, using predictive analytics. Shorter supply chains can allow for greater levels of control and visibility, however, nearshoring brings with it its own set of challenges.
Applying Agile Software Development Concepts To Pharmaceutical Manufacturing And Distribution Footprint Optimisation
How pharmaceutical companies can take learnings from high-growth technology businesses to continuously optimise their footprint and pay down footprint design debt. Continued aftereffects of the COVID-19 pandemic, Russia's invasion of Ukraine and surging inflation are the latest triggers for pharmaceutical companies to rethink how they manufacture and distribute products to their customers.
Innovative Routes To Market: Rethinking The Life Sciences Distribution Model
ASK THE ANALYST Email Print Bookmark 11 Oct 2016 Opinion Executive Summary Life sciences business should look at new routes to market in order to innovate and reap the benefits, both for themselves and for the patient, says Lee Feander, life sciences director at Deloitte. Already Registered? Sign in to continue reading. New to Scrip?
Innovative Routes To Market: Rethinking The Life Sciences Distribution Model
All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please Note: Only individuals with active subscriptions will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Lee
Contact Lee, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack